DDInter548 DDInter1913
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Valproic acid
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) UGT2B7
UGT2B7 {u} (Gene) is bound by {v} (Compound) Valproic acid
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valproic acid
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2A6
CYP2A6 {u} (Gene) is bound by {v} (Compound) Bupropion
Bupropion {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valproic acid
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} (Compound) resembles {v} (Compound) Tripelennamine
Tripelennamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valproic acid
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Valproic acid
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Diethylstilbestrol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Valproic acid (Compound)
Diethylstilbestrol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with UGT2B7 (Gene) and UGT2B7 (Gene) is bound by Valproic acid (Compound)
Diethylstilbestrol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Valproic acid
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Diethylstilbestrol (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Bupropion (Compound) and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Diethylstilbestrol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Valproic acid
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen (Compound) resembles Tripelennamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Valproic acid
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Valproic acid (Compound)
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid